) expanded its existing collaboration with Exosome Diagnostics
for the development of a first-of-its-kind, non-invasive
molecular in-vitro diagnostics that will help diagnose and
monitor cancer patients. Qiagen will gain exclusive rights to
market and sell the test globally. Financial details of the
transaction, however, remain undisclosed.
The proposed test will use exosomes to detect certain
mutations of an undisclosed gene associated with non-small cell
lung cancer (NSCLC) and other tumors. Compared with current
molecular diagnostics requiring tissue biopsy, the test will
enable detection of cancer biomarkers in plasma and therefore,
reduce both cost and patient risk.
The development of this technologically advanced test promises
to improve cancer treatment methods. It will enable physicians to
diagnose and monitor a patient's disease more comprehensively and
in a time-effective manner. The test can be coupled with new
anticancer therapeutics. The collaboration will see both
companies combining their respective expertise to deliver
advanced clinical research and healthcare standards by automating
sample-to-result workflows and increasing cost efficiency and
In a bid to strengthen its suite of diagnostic tests, Qiagen
had announced a strategic partnership with Exosome on Jul 23,
2013. The deal was signed to develop an all inclusive range of
biofluid nucleic acid kits. Qiagen has set a tentative target to
launch the first set of products under this range in the second
quarter of 2014.
Currently, Qiagen has a Zacks Rank #2 (Buy). Other
better-ranked stocks in the broader healthcare sector include
Emergent BioSolutions, Inc. (
. All these companies sport a Zacks Rank #1 (Strong Buy).
AFFYMETRIX INC (AFFX): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
EMERGENT BIOSOL (EBS): Free Stock Analysis
QIAGEN NV (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.